Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: A Cancer Journal for Clinicians 68 394-424

[2] Ferlay J(2017)The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015 JAMA Oncology 3 1683-1691

[3] Soerjomataram I(2018)Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Annals of Oncology 29 iv238-255

[4] Akinyemiju T(2017)Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial The Lancet 389 56-66

[5] Abera S(2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial Lancet 391 1163-1173

[6] Ahmed M(2020)Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma New England Journal of Medicine 382 1894-1905

[7] Vogel A(2012)Illness experience in patients with hepatocellular carcinoma: An interpretative phenomenological analysis study European Journal of Gastroenterology and Hepatology 24 203-208

[8] Cervantes A(2014)Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): A patient interview study Supportive Care in Cancer 22 919-926

[9] Chau I(1993)The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology Journal of the National Cancer Institute 85 365-376

[10] Bruix J(2004)Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18 European Journal of Cancer 40 2439-2444

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: A Cancer Journal for Clinicians 68 394-424

[2] Ferlay J(2017)The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015 JAMA Oncology 3 1683-1691

[3] Soerjomataram I(2018)Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Annals of Oncology 29 iv238-255

[4] Akinyemiju T(2017)Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial The Lancet 389 56-66

[5] Abera S(2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial Lancet 391 1163-1173

[6] Ahmed M(2020)Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma New England Journal of Medicine 382 1894-1905

[7] Vogel A(2012)Illness experience in patients with hepatocellular carcinoma: An interpretative phenomenological analysis study European Journal of Gastroenterology and Hepatology 24 203-208

[8] Cervantes A(2014)Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): A patient interview study Supportive Care in Cancer 22 919-926

[9] Chau I(1993)The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology Journal of the National Cancer Institute 85 365-376

[10] Bruix J(2004)Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18 European Journal of Cancer 40 2439-2444